Michael Shia, Ph.D.

Dr. Michael A. Shia, PhD is the Director of Immunology at 21st Century Biochemicals, Inc. Dr. Shia received his Ph.D. in Biochemistry from Boston University in 1984, and was one of the first to demonstrate that the insulin receptor is a tyrosine kinase. Dr. Shia did his postdoctoral work at MIT's Whitehead Institute studying cell trafficking pathways and the structure function relationships of receptors with Dr. Harvey Lodish.  Dr. Shia joined the faculty of Boston University School of Medicine in 1990 where he continued his work on the cell and molecular biology of receptors and the trafficking of proteins in the cell. He moved to U.S. Genomics Inc., as a principal investigator, where he developed and demonstrated the feasibility of their GeneEngine technology for use as a broadband pathogen detector for use in biodefense. He moved on to found Cambridgeport Consultants were he assisted emerging biotech companies develop scientific plans and funding strategies. He was recruited to 21st Century Biochemicals to head their Immunology group and to develop applications for their antibody and peptide business. Dr. Shia has over two dozen papers and reviews. He has served on NIH SBIR study sections and is a current member and participant in CIMIT (Center for Integrating Medicine and Innovative Technology).

 

 




 

Jordan B. Fishman, Ph.D.
Eric Berg, PhD
Michael Shia, Ph.D.
Pamela Crowley
Clare Fishman
Veronika Skoromnik

 

 

260 Cedar Hill Street, Marlboro, MA 01752 Phone508.303.8222 Toll-free Phone1.877.217.8238 Fax Number508.303.8333 Email
©2003-2012 Twentyfirst Century Biochemicals, Inc. All rights reserved.
Prices subject to change without notice, not responsible for typographical errors.
Epi-SynH3™, Epi-SynH4™, and MS Check™ are wholly owned trademarks of Twentyfirst Century Biochemicals, Inc;
Epi-Plus® is a registered trademark of Twentyfirst Century Biochemicals, Inc. and Novus Biologicals, LLC.

Website Development by Greenwing Solutions, Inc.